Shijin Ma, CEO of Tsingke Biotech, opened the salon by calling for deeper coordination across the value chain. As the sector matures, the ability to bridge gaps between synthesis, delivery, and clinical validation has become the primary benchmark for competitiveness. The technical sessions underscored this, with Dr. Jun Bai of Haichang Biotech mapping the evolution of siRNA therapeutics, specifically highlighting advances in antibody-oligonucleotide conjugates and targeted delivery to adipose and kidney tissues.
Tsingke Biotech Unites Experts to Chart Future of RNA Therapeutics
At the Hilton Shanghai Zhangjiang, industry leaders and researchers gathered to navigate the shift in China’s nucleic acid sector from basic technology adoption to innovation-driven growth. The summit emphasized that the next generation of oligonucleotide drugs hinges on integrating advanced delivery systems with rigorous regulatory and manufacturing strategies.
Regulatory and development hurdles remained at the forefront of the discussion. Dr. Yaning Wang, formerly of the FDA, dissected critical approval cases to clarify how developers should approach surrogate endpoints and evidence generation. Meanwhile, Dr. Chengjiang Zhao of Youjia (Hangzhou) Biomedical Technology detailed the complexities of CMC strategy, stressing that early-stage planning in process development and toxicology is non-negotiable for successful IND submissions. The event concluded with a consensus that long-term success requires an integrated ecosystem approach, combining artificial intelligence with robust GMP-grade manufacturing to accelerate global development timelines.
Comments (0)
No comments yet. Be the first!